Q4 2017 13F Holders as of 31 Dec 2017
-
Type / Class
-
Debt / DBCV 3.250%12/1
-
Market price (% of par)
-
121.74%
-
Total 13F principal
-
$19,628,000
-
Principal change
-
-$244,255,006
-
Total reported market value
-
$23,944,000
-
Number of holders
-
4
-
Value change
-
-$251,798,785
-
Number of buys
-
3
-
Number of sells
-
27
Institutional Holders of SUCAMPO PHARMACEUTICALS INC - DBCV 3.250%12/1 as of Q4 2017
As of 31 Dec 2017,
SUCAMPO PHARMACEUTICALS INC - DBCV 3.250%12/1 was held by
4 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$19,628,000
in principal (par value) of the bond.
The largest 4 bondholders included
Athyrium Capital Management, LP, UBS Group AG, GABELLI FUNDS LLC, and Worth Venture Partners, LLC.
This page lists
4
institutional bondholders reporting positions
for the Q4 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.